On this page

Sterile Water

Water · Injection, Solution

Prescription ANDA TE AP Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Sterile Water
Generic name
Water
Dosage form
Injection, Solution
Route
Intravenous
Marketing category
ANDA · ANDA
Labeler
Baxter Healthcare Company
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
12
Packages
22
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Water 1 mL/mL 1053154 View
Water 100 mL/100mL 1053154 View
Water 1000 mL/1000mL 1053154 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intravenous
Presentations
34

Regulatory status

Source: Drugs@FDANDC Directory
Application number
206369
Application type
ANDA · Abbreviated New Drug Application
Approval date
September 2, 2015
Sponsor
HIKMA
Products on application
2
Submissions recorded
1
Products approved under application 206369.
Product Trade name Form Strength Ingredient Status TE Flags
206369-001 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Prescription AP
206369-002 STERILE WATER FOR INJECTION LIQUID STERILE WATER FOR INJECTION Discontinued —

Therapeutic equivalence

Source: Orange Book
TE code
AP
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 206369.
Type No. Action Status Date Review
Original application 1 Approved September 2, 2015 Standard

Review documents

  • 0 · Original application · October 22, 2015
  • 0 · Original application · September 4, 2015

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251102). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251102 HUMAN PRESCRIPTION DRUG · 20251029 HUMAN PRESCRIPTION DRUG · 20250108 HUMAN PRESCRIPTION DRUG · 20230508

Boxed Warning

openFDA Drug Labeling

Pharmacy Bulk Package — Not for Direct Infusion. FOR USE ONLY WITH AUTOMATED COMPOUNDING DEVICES.

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Sterile Water for Injection, USP is indicated for use only as a solvent or diluent vehicle for parenterally administered drugs or solutions and as a source of water for parenteral fluid replenishment after suitable additives are introduced. For intravenous administration, an osmolar concentration not less than two-fifths (0.4) of the normal osmolarity of the extracellular fluid (280 mOsmol/liter) is essential to avoid intravascular hemolysis.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible. Sterile Water for Injection, USP in the Pharmacy Bulk Package is intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of Sterile Water for Injection, USP. DIRECTIONS FOR USE OF VIAFLEX PLASTIC PHARMACY BULK PACKAGE CONTAINER To Open Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly, if leaks are found, discard solution as sterility may be impaired. For compounding only, not for direct infusion. Preparation for Admixing 1. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). 2. Suspend container from eyelet support. 3. Remove plastic protector from outlet port at bottom of container. 4. Attach solution transfer set. Refer to complete directions accompanying set. Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. 5. VIAFLEX containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry. 6. Once container closure has been penetrated, withdrawal of contents should be completed without delay. After initial entry, maintain contents at room temperature (25°C/77°F) and dispense within 4 hours.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Sterile Water for Injection, USP is a hemolytic agent due to its hypotonicity. Therefore, it is contraindicated for intravenous administration without additives.

WARNINGS FOR DILUTION ONLY. Do not heat over 66°C (150°F). This preparation is solute-free and its entry into the circulation undiluted will cause hemolysis . Absorption of large amounts of Sterile Water for Injection, USP with additives can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Adverse Reactions

openFDA Drug Labeling

Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination. To report SUSPECTED ADVERSE REACTIONS, contact Medefil, Inc., at 1-630-682-4600 or www.medefilinc.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination. To report SUSPECTED ADVERSE REACTIONS, contact Medefil, Inc., at 1-630-682-4600 or www.medefilinc.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Drug Interactions

openFDA Drug Labeling

Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available. When diluting or dissolving drugs, mix thoroughly and use promptly. Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion. Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available. When diluting or dissolving drugs, mix thoroughly and use promptly. Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute. Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion.

Description

openFDA Drug Labeling

DESCRIPTION: Sterile Water for Injection, USP is a sterile, nonpyrogenic, solute-free preparation of distilled water for injection. It is for use only as a sterile solvent or diluent vehicle for drugs or solutions suitable for parenteral administration. The pH is 5.5 (5.0 to 7.0). Sterile Water for Injection contains no bacteriostat, antimicrobial agent or added buffer and is intended only for single dose injection after admixture with an appropriate solute or solution. When smaller amounts are required, the unused portion should be discarded. Sterile Water for Injection is a pharmaceutic aid (vehicle) and parenteral fluid replenisher after addition of an appropriate solute. Water for Injection, USP is chemically designated H 2 O. The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers ( free flex ® bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container’s chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.

OVERDOSAGE Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of fluid overload except possibly in neonates or very small infants. In the event these should occur, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS , PRECAUTIONS and ADVERSE REACTIONS .

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Sterile Water for Injection, USP is supplied in a single-dose 1000 mL flexible plastic container (NDC 0409-7990-09 Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA , Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA and 0990-7990-09 , ). ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time. INSTRUCTIONS FOR USE To Open Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. To Add Medication Prepare additive port. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication. The additive port may be protected by covering with an additive cap. Mix container contents thoroughly. Preparation for Administration (Use aseptic technique) Close flow control clamp of administration set. Remove cover from outlet port at bottom of container. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton. Suspend container from hanger. Squeeze and release drip chamber to establish proper fluid level in chamber. Open flow control clamp and clear air from set. Close clamp. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture. Regulate rate of administration with flow control clamp. WARNING: DO NOT USE FLEXIBLE CONTAINER IN SERIES CONNECTIONS. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Revised: September, 2018 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA EN-4689

Adverse event reports

Source: openFDA FAERS
19,134
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: WATER. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II June 15, 2022 Mckesson Medical-Surgical Inc. Corporate Office cGMP deviations: Temperature abuse Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0517-3010-25 0517-3010 American Regent, Inc. 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-3010-25) / 10 mL in 1 VIAL, SINGLE-DOSE (0517-3010-01) April 22, 2022
0517-3020-25 0517-3020 American Regent, Inc. 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-3020-25) / 20 mL in 1 VIAL, SINGLE-DOSE (0517-3020-01) April 22, 2022
0338-0013-04 0338-0013 Baxter Healthcare Company 1000 mL in 1 BAG (0338-0013-04) June 30, 1982
0338-0013-06 0338-0013 Baxter Healthcare Company 2000 mL in 1 BAG (0338-0013-06) June 30, 1982
0338-0013-08 0338-0013 Baxter Healthcare Company 3000 mL in 1 BAG (0338-0013-08) June 30, 1982
0338-0013-29 0338-0013 Baxter Healthcare Company 5000 mL in 1 BAG (0338-0013-29) June 30, 1982
17271-750-07 17271-750 Becton Dickinson and Company 10 BAG in 1 CASE (17271-750-07) / 1000 mL in 1 BAG February 28, 2020
72572-747-10 72572-747 Civica, Inc. 10 VIAL in 1 CARTON (72572-747-10) / 10 mL in 1 VIAL (72572-747-01) February 23, 2022
63323-178-76 63323-178 Fresenius Kabi USA, LLC 10 BAG in 1 CASE (63323-178-76) / 1000 mL in 1 BAG November 24, 2017
0404-9781-10 0404-9781 Henry Schein, Inc. 1 VIAL in 1 BAG (0404-9781-10) / 10 mL in 1 VIAL August 28, 2025
0143-9339-12 0143-9339 Hikma Pharmaceuticals USA Inc. 12 BAG in 1 CASE (0143-9339-12) / 1000 mL in 1 BAG May 5, 2023
0641-6147-10 0641-6147 Hikma Pharmaceuticals USA Inc. 10 VIAL in 1 CARTON (0641-6147-10) / 10 mL in 1 VIAL (0641-6147-01) September 3, 2015
0641-6147-25 0641-6147 Hikma Pharmaceuticals USA Inc. 25 VIAL in 1 CARTON (0641-6147-25) / 10 mL in 1 VIAL (0641-6147-01) September 3, 2015
0990-7118-07 0990-7118 ICU Medical Inc. 6 BAG in 1 CASE (0990-7118-07) / 2000 mL in 1 BAG June 1, 2019
0990-7990-09 0990-7990 ICU Medical Inc. 12 POUCH in 1 CASE (0990-7990-09) / 1 BAG in 1 POUCH / 1000 mL in 1 BAG October 1, 2019
64253-020-21 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-21) / 1 mL in 1 SYRINGE, PLASTIC January 27, 2020
64253-020-23 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-23) / 3 mL in 1 SYRINGE, PLASTIC January 27, 2020
64253-020-25 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-25) / 5 mL in 1 SYRINGE, PLASTIC September 21, 2020
64253-020-30 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-30) / 10 mL in 1 SYRINGE, PLASTIC January 27, 2020
64253-020-35 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-35) / 5 mL in 1 SYRINGE, PLASTIC January 27, 2020
64253-020-52 64253-020 Medefil, Inc. 60 SYRINGE, PLASTIC in 1 BOX (64253-020-52) / 2.5 mL in 1 SYRINGE, PLASTIC January 27, 2020
64253-020-91 64253-020 Medefil, Inc. 10 SYRINGE, PLASTIC in 1 BOX (64253-020-91) / 10 mL in 1 SYRINGE, PLASTIC September 21, 2020
0517-3010 0517-3010 American Regent, Inc. — April 22, 2022
0517-3020 0517-3020 American Regent, Inc. — April 22, 2022
0338-0013 0338-0013 Baxter Healthcare Company — June 30, 1982
17271-750 17271-750 Becton Dickinson and Company — February 28, 2020
72572-747 72572-747 Civica, Inc. — February 23, 2022
63323-178 63323-178 Fresenius Kabi USA, LLC — November 24, 2017
0404-9781 0404-9781 Henry Schein, Inc. — August 28, 2025
0143-9339 0143-9339 Hikma Pharmaceuticals USA Inc. — May 5, 2023
0641-6147 0641-6147 Hikma Pharmaceuticals USA Inc. — September 3, 2015
0990-7118 0990-7118 ICU Medical Inc. — June 1, 2019
0990-7990 0990-7990 ICU Medical Inc. — October 1, 2019
64253-020 64253-020 Medefil, Inc. — January 27, 2020

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 12 sections on this page.